Therapeutic Response

v::ALK status confers therapeutic sensitivity to Brigatinib in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Alunbrig (brigatinib) [product information]. EMA. The European Medicines Agency (EMA) has authorized brigatinib as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) who were previously not treated with an ALK inhibitor.
Alunbrig (brigatinib) [product information]. EMA. The European Medicines Agency (EMA) has authorized brigatinib as a monotherapy for the treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.
Alunbrig (brigatinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to brigatinib for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test.